Psilocybin microdosing study for cognition and mood
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether very small, repeated doses of psilocybin (a substance found in certain mushrooms) can improve thinking, mood, and quality of life. It is for adults who have never used psychedelics and are in good general health, both mentally and physically.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have never used psychedelic drugs before.
- You can read, speak, and understand English.
- If you are a woman who could become pregnant, you must use a highly effective birth control method.
- You do not have a current mood disorder, psychotic disorder, or developmental condition (like schizophrenia or bipolar disorder).
- You do not have a serious medical condition (like cancer, epilepsy, or a history of head injury with prolonged unconsciousness), and you are able to have an MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if psilocybin, a substance found in certain mushrooms, can help people with various mental health symptoms that affect daily life. You would take a single dose in a supervised setting and be monitored for changes in your mood and well-being.
This trial tests whether a single dose of psilocybin can help people with treatment-resistant depression by changing how they focus on themselves. It aims to understand how psilocybin affects brain activity and self-related thinking.
This trial tests how psilocybin, a psychedelic substance, affects your thinking, memory, and brain activity. Researchers want to understand these effects in healthy adults who have used psychedelics before.
This study tests whether a single dose of psilocybin (a psychedelic compound) can help treat depression by looking at brain changes on MRI. It is designed for people with moderate-to-severe depression who have not responded well to other treatments.
This Phase 1/2 study tests psilocybin to see how it affects brain signals and the “content” of thoughts while you are monitored during the study. Because participants must be generally healthy and mentally stable, it may be an option if you meet those safety and medication rules and are comfortable having your brain activity measured.
This study tests whether combining mindfulness training with a single dose of psilocybin (a psychedelic found in certain mushrooms) can help healthy adults. It aims to explore how these two approaches together might improve well-being.
Hear when a new Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.